Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050008 | 0.98 | PTGDR2 (0.40) | PTGDR2PTGS2NOS1BCHEACHE | |
| SCHEMBL30028865 | 0.88 | HTR2C (0.39) | HTR2C | |
| SCHEMBL3453584 | 0.88 | HTR2C (0.39) | HTR2C | |
| Formaldehyde SCHEMBL28173686 | 0.87 | PTGDR2 (0.37) | PTGDR2PTGS2NOS1CELCCNE1 | |
| SCHEMBL42781 | 0.83 | PTGDR2 (0.48) | PTGDR2PTGS2NOS1BCHEACHE | |
| SCHEMBL20133796 | 0.81 | ESR2 (0.35) | PTGDR2PTGS2NOS1HTR2CHTR1D | |
| Benzene SCHEMBL27853973 | 0.80 | PTGDR2 (0.52) | PTGDR2PTGS2BCHEACHECEL | |
| SCHEMBL779938 | 0.80 | CHRNB4 (0.46) | PTGDR2PTGS2BCHEACHECEL | |
| SCHEMBL19144813 | 0.79 | CEL (0.41) | PTGDR2PTGS2BCHEACHECEL | |
| SCHEMBL11836887 | 0.78 | HTR2C (0.60) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| CN-103570620-B | The luxuriant and rich with fragrance compounds of a kind of 1,12-imino group benzo [c], intermediate and preparation method and application | 昆山维信诺显示技术有限公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-103787826-B | Cycloheptane compounds and the liquid-crystal composition that contains this compound and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-05-18 | — | — | CN | disclosed |
| CN-103787826-A | Cycloheptane compound, liquid crystal composition containing compound and application of cycloheptane compound | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103570620-A | 1,12-iminobenzo[c]phenanthrene compound, intermediate, preparation method and application of compound | KUNSHAN VISIONOX DISPLAY TECH | 2014-02-12 | — | — | CN | disclosed |
| CN-101544892-B | Method for synthesizing diaryl acetylene monomer liquid crystal | SHIJIAZHUANG YONGSHENG HUATSING LIQUID CRYSTAL CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-101544892-A | Method for synthesizing diaryl acetylene monomer liquid crystal | SHIJIAZHUANG YONGSHENG HUATSIN | 2009-09-30 | — | — | CN | disclosed |
| WO-2009055674-A1 | PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055674-A1 | PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| CN-100415730-C | Benzofuran derivative and its prepn and use | SHIJIAZHUANG YONGSHENG HUATSIN (CN) | 2008-09-03 | — | — | CN | disclosed |
| US-7084176-B2 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| CN-1684944-A | method for copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2005-10-19 | — | — | CN | disclosed |
| EP-1534671-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6888032-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| CN-1529692-A | N-arylphenylacetamide derivatives and medicinal compositions containing same | 大日本制药株式会社 | 2004-09-15 | — | — | CN | disclosed |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | disclosed |
| EP-1403235-A1 | N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004013094-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | PTGDR2 2315/4885PTGS2 488/4885NOS1 609/4885 |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | PTGDR2 2341/4885PTGS2 511/4885NOS1 625/4885 |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OXGR1, OCIAD1 | PTGDR2 1521/4885PTGS2 2533/4885NOS1 903/4885 |
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | HRH2, CCR8, CYP2C8 | PTGDR2 714/4885PTGS2 168/4885NOS1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.